Wells Fargo raised the firm’s price target on Relay Therapeutics (RLAY) to $21 from $17 and keeps an Overweight rating on the shares. The firm believes the update for zovegalisib was interesting and incorporated the first line opportunity in its model. That said, Wells awaits for durability data to better understand where zovegalisib stands vs. other PI3Ki competitors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target raised to $22 from $13 at Goldman Sachs
- Relay Therapeutics price target raised to $19 from $17 at Citizens
- Analyst Reiterates Buy on Relay Therapeutics, Citing Promising Zovega mBC Data, Favorable Safety Profile, and Phase 3 First-Line Breast Cancer Upside
- Relay Therapeutics advances zovegalisib combo in breast cancer
- Relay Therapeutics’ combination for breast cancer shows efficacy and safetyPfizer